BioLineRx (BLRX) vs Ensysce Biosciences (ENSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
BioLineRx is the larger company by market cap ($11.0 million vs $10.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BLRX | ENSC |
|---|---|---|
| Share price | $2.22 | $0.527 |
| Market cap | $11.03M | $10.25M |
| 1-day change | -0.18% | +15.07% |
| YTD return | -20.00% | — |
| 1-year return | -46.99% | — |
| 5-year return | -98.19% | — |
| EPS (TTM) | $0.00 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.16 | $2.75 |
| 52-week low | $2.15 | $0.23 |
| Distance from 52-week high | -46.73% | -80.84% |
| Analyst consensus | none | none |
| Avg. price target upside | +892.78% | +1465.46% |
| Average volume | 16.39K | 14.43M |
| Shares outstanding | 4.98M | 19.46M |
| Employees | 20 | 8 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About BioLineRx
BLRX stock →BioLineRx Ltd., a biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes GLIX1, an oral, small molecule targeting DNA damage response in glioblastoma and other cancers; and APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Health Care · Biotechnology: Pharmaceutical Preparations · 20 employees
About Ensysce Biosciences
ENSC stock →Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug technology.
Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees
BLRX vs ENSC FAQ
Which is bigger, BioLineRx or Ensysce Biosciences?
BioLineRx (BLRX) is larger, with a market capitalization of $11.03M compared with $10.25M for Ensysce Biosciences (ENSC).
Are BioLineRx and Ensysce Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.